促炎细胞因子在多系统萎缩患者的血清中升高。
Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy.
机构信息
Department of Clinical Sciences, Section for Psychiatry, Lund University, Lund, Sweden.
出版信息
PLoS One. 2013 Apr 23;8(4):e62354. doi: 10.1371/journal.pone.0062354. Print 2013.
Abstract
BACKGROUND
Despite several lines of evidence from preclinical and post-mortem studies suggesting that inflammation is involved in Multiple System Atrophy (MSA), no previous studies have measured peripheral indices of inflammation in MSA patients.
METHODS
We measured C-reactive protein, interleukin (IL)-6, soluble IL-2 receptor and tumor necrosis factor (TNF)-α in blood samples from MSA patients (n = 14) and healthy controls (n = 40).
RESULTS
IL-6 and TNF-α were significantly elevated in MSA patients compared to healthy controls. After controlling for the potentially confounding effects of age, gender, and somatic co-morbidities, a diagnosis of MSA was still significantly associated with high levels of TNF-α. Higher TNF-α levels were associated with less severe motor symptoms and earlier disease stage.
CONCLUSIONS
Our findings are in line with the hypothesis that inflammation might be involved at an early stage of MSA pathophysiology.
摘要
背景
尽管来自临床前和尸检研究的数条证据表明炎症参与了多系统萎缩（MSA），但之前没有研究测量过 MSA 患者的外周炎症指标。
方法
我们测量了 MSA 患者（n=14）和健康对照组（n=40）的血液样本中的 C 反应蛋白、白细胞介素（IL）-6、可溶性 IL-2 受体和肿瘤坏死因子（TNF）-α。
结果
与健康对照组相比，MSA 患者的 IL-6 和 TNF-α 显著升高。在控制年龄、性别和躯体合并症等潜在混杂因素的影响后，MSA 的诊断仍与高水平的 TNF-α显著相关。较高的 TNF-α水平与较轻的运动症状和更早的疾病阶段相关。
结论
我们的发现与炎症可能在 MSA 病理生理学的早期阶段发生的假设一致。
相似文献
1
Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy.
PLoS One. 2013 Apr 23;8(4):e62354. doi: 10.1371/journal.pone.0062354. Print 2013.
2
Serum Lymphocyte-Associated Cytokine Concentrations Change More Rapidly over Time in Multiple System Atrophy Compared to Parkinson Disease.
Neuroimmunomodulation. 2016;23(5-6):301-308. doi: 10.1159/000460297. Epub 2017 Apr 11.
3
Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study.
J Neuroinflammation. 2017 Apr 24;14(1):89. doi: 10.1186/s12974-017-0863-0.
4
Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.
PLoS One. 2012;7(10):e47387. doi: 10.1371/journal.pone.0047387. Epub 2012 Oct 17.
5
Diagnostic value and correlation analysis of serum cytokine levels in patients with multiple system atrophy.
Front Cell Neurosci. 2024 Sep 4;18:1459884. doi: 10.3389/fncel.2024.1459884. eCollection 2024.
6
Serum lipid levels are associated with the prevalence but not with the disease progression of multiple system atrophy in a Chinese population.
Neurol Res. 2014 Feb;36(2):150-6. doi: 10.1179/1743132813Y.0000000277. Epub 2013 Dec 6.
7
Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes.
Chin J Integr Med. 2015 Feb;21(2):108-14. doi: 10.1007/s11655-014-1792-0. Epub 2014 Dec 19.
8
Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study.
Parkinsonism Relat Disord. 2019 Aug;65:3-12. doi: 10.1016/j.parkreldis.2019.05.040. Epub 2019 Jun 3.
9
Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: A pilot study.
Parkinsonism Relat Disord. 2019 Mar;60:105-110. doi: 10.1016/j.parkreldis.2018.09.012. Epub 2018 Sep 11.
10
Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy.
Parkinsonism Relat Disord. 2018 Dec;57:58-62. doi: 10.1016/j.parkreldis.2018.07.017. Epub 2018 Jul 26.
引用本文的文献
1
Research progress of chronic fatigue in neurodegenerative diseases.
Neurol Sci. 2025 Jun 10. doi: 10.1007/s10072-025-08254-z.
2
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives.
J Neural Transm (Vienna). 2025 May 20. doi: 10.1007/s00702-025-02930-2.
3
Oligodendrocyte-specific overexpression of human alpha-synuclein results in elevated MBP levels and inflammatory responses in TgM83 mice, mimicking the pathological features of multiple system atrophy.
Acta Neuropathol Commun. 2025 May 7;13(1):94. doi: 10.1186/s40478-025-02014-y.
4
Diagnostic value and correlation analysis of serum cytokine levels in patients with multiple system atrophy.
Front Cell Neurosci. 2024 Sep 4;18:1459884. doi: 10.3389/fncel.2024.1459884. eCollection 2024.
5
The Movement Disorder Society Criteria: Its Clinical Usefulness in Multiple System Atrophy.
Intern Med. 2024 Nov 1;63(21):2903-2912. doi: 10.2169/internalmedicine.3275-23. Epub 2024 Mar 18.
6
Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments.
J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1987-2002. doi: 10.1002/jcsm.13312. Epub 2023 Aug 13.
7
Inflammation in multiple system atrophy.
Front Immunol. 2023 Jun 22;14:1214677. doi: 10.3389/fimmu.2023.1214677. eCollection 2023.
8
Urinary tract infections trigger synucleinopathy via the innate immune response.
Acta Neuropathol. 2023 May;145(5):541-559. doi: 10.1007/s00401-023-02562-4. Epub 2023 Mar 30.
9
The Peripheral Immune Traits Changed in Patients with Multiple System Atrophy.
Brain Sci. 2023 Jan 26;13(2):205. doi: 10.3390/brainsci13020205.
10
Exploring the mechanism of astragalus membranaceus in the treatment of multiple system atrophy based on network pharmacology and molecular docking.
Medicine (Baltimore). 2023 Feb 3;102(5):e32523. doi: 10.1097/MD.0000000000032523.
本文引用的文献
1
Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.
PLoS One. 2012;7(10):e47387. doi: 10.1371/journal.pone.0047387. Epub 2012 Oct 17.
2
The neuropathology, pathophysiology and genetics of multiple system atrophy.
Neuropathol Appl Neurobiol. 2012 Feb;38(1):4-24. doi: 10.1111/j.1365-2990.2011.01234.x.
3
The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease.
Psychosomatics. 2010 Nov-Dec;51(6):474-9. doi: 10.1176/appi.psy.51.6.474.
4
Microglia in neurodegenerative disease.
Nat Rev Neurol. 2010 Apr;6(4):193-201. doi: 10.1038/nrneurol.2010.17. Epub 2010 Mar 16.
5
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).
Mov Disord. 2010 Jan 15;25(1):97-107. doi: 10.1002/mds.22732.
6
Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance.
Neurosci Lett. 2010 Jan 1;468(1):56-8. doi: 10.1016/j.neulet.2009.10.062. Epub 2009 Oct 24.
7
Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy.
Mov Disord. 2007 Nov 15;22(15):2196-203. doi: 10.1002/mds.21671.
8
Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires.
J Pain Symptom Manage. 2006 Nov;32(5):420-32. doi: 10.1016/j.jpainsymman.2006.05.021.
9
Health-related quality of life in multiple system atrophy.
Mov Disord. 2006 Jun;21(6):809-15. doi: 10.1002/mds.20808.
10
Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy.
Neurosci Lett. 2005 Feb 21;374(3):218-21. doi: 10.1016/j.neulet.2004.10.056.
Zotero 插件